Evidence map›Paper›PMID 34039302›Full record

Trial reportBMC neurology2021

Assessing migraine patients with multifocal pupillographic objective perimetry.

Eman N Ali, Corinne F Carle, Christian J Lueck, Maria Kolic, Ted Maddess

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Blue Light-Ocular and Systemic Damaging Effects: A Narrative Review.International journal of molecular sciences · 2023
    Review
  4. Rapid, non-contact multifocal visual assessment in multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eman N AliEccles Institute of Neuroscience, the John Curtin School of Medical Research, Australian National University, Acton, ACT, Australia.ORCID https://orcid.org/0000-0003-2102-6472
Corinne F CarleEccles Institute of Neuroscience, the John Curtin School of Medical Research, Australian National University, Acton, ACT, Australia.ORCID https://orcid.org/0000-0002-3309-9073
Christian J LueckAustralian National University Medical School, Acton, ACT, Australia.ORCID https://orcid.org/0000-0003-1537-7612
Maria KolicEccles Institute of Neuroscience, the John Curtin School of Medical Research, Australian National University, Acton, ACT, Australia.ORCID https://orcid.org/0000-0002-8877-3264
Ted MaddessEccles Institute of Neuroscience, the John Curtin School of Medical Research, Australian National University, Acton, ACT, Australia. ted.maddess@anu.edu.au.ORCID http://orcid.org/0000-0003-4591-3658

Funding

Australian Research Council CE0561903
6 · The paper itself

Abstract

backgroundTo establish the effects of stimulating intrinsically-photosensitive retinal ganglion cells (ipRGCs) on migraine severity, and to determine if migraine produces objectively-measured visual field defects.

methodsA randomized, open labelled, crossover study tested migraineurs and normal controls using multifocal pupillographic objective perimetry (mfPOP) with 44 test-regions/eye. A slow blue protocol (BP) stimulated ipRGCs, and a fast yellow protocol (YP) stimulated luminance channels. Migraine diaries assessed migraine severity. Per-region responses were analyzed according to response amplitude and time-to-peak.

resultsThirty-eight migraineurs (42.0 ± 16.5 years, 23 females) and 24 normal controls (39.2 ± 15.2 years, 14 females) were tested. The proportion of subjects developing a migraine did not differ after either protocol, either during the 1st day (odds ratio 1.0; 95% confidence interval 0.2-4.4, p = 0.48) or during the first 3 days after testing (odds ratio 0.8; 95% confidence interval 0.3-2.1, p = 0.68). Migraine days/week did not increase following testing with either protocol in comparison to the baseline week (1.4 ± 1.6 pre-testing (mean ± SD), 1.3 ± 1.4 post-BP, and 1.3 ± 1.2 post-YP; p = 0.96), neither did other measures of severity. Migraine occurring up to 2 weeks before testing significantly lowered amplitudes, - 0.64 ± 0.14 dB (mean ± SE), while triptan use increased amplitudes by 0.45 ± 0.10 dB, both at p < 0.001.

conclusionsStimulating ipRGCs did not affect migraine occurrence or severity. Pupillary response characteristics were influenced by the occurrence of a recent migraine attack and a history of triptan use.

Indexed as

AdultCross-Over StudiesFemaleHumansMaleMiddle AgedMigraine DisordersPupilVisual FieldsVisual Field TestsMelanopsinMigraineMultifocal pupillographyPhotosensitivityTrigeminovascular pathway

Identifiers

PMID34039302
PMCPMC8152334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.